RESEARCH ARTICLE

Obesity Does Not Influence Outcomes in Hepatocellular Carcinoma Patients following Curative Hepatectomy

Zhe Guo¹,², Jun Zhang³, Jing-Hang Jiang¹,⁴, Le-Qun Li⁴*, Bang-De Xiang¹*

1 Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, P.R. China, 2 Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Wuhan, P.R. China, 3 Department of Ultrasound, Wuhan NO. 1 Hospital, Wuhan, P.R. China, 4 Department of General Surgery, The Second People’s Hospital of Jing Men, Jingmen, P.R. China

☯ These authors contributed equally to this work.

* xiaopushu-213@163.com (LQL); zheguophd@163.com (BDX)

Abstract

Background

Whether obesity affects surgical outcomes in patients with hepatocellular carcinoma (HCC) is controversial. Here we retrospectively evaluated the impact of obesity on outcomes in HCC patients after curative hepatectomy.

Methods

Patients with Child-Pugh A liver function who underwent curative hepatectomy between 2006 and 2010 were categorized as obese (BMI ≥25 kg/m², n = 68) and non-obese (<25 kg/m², n = 242). To reduce interference from baseline differences between the two groups, propensity score-matched analysis was performed in the ratio 1:2 using a caliper width of 0.1. Surgical outcomes were compared for 61 obese and 115 non-obese patients.

Results

Obese patients had higher levels of albumin and aspartate aminotransferase, and more solitary tumors compared to the non-obese patients (all \( P < 0.05 \)). In the propensity-matched cohort, baseline characteristics did not differ between the two groups (all \( P > 0.05 \)). Obese and non-obese patients had comparable 30-day mortality (1.6% vs. 2.6%, \( P = 1.000 \)), 90-day mortality (3.3% vs. 4.3%, \( P = 1.000 \)), and incidence of postoperative complications (19.7% vs. 18.3%, \( P = 0.819 \)). Overall survival at 1, 3, and 5 years was similar for obese patients (83.6%, 63.6%, 41.6%) as for non-obese patients (80.9%, 65.9%, 49.1%; \( P = 0.358 \)). Disease-free survival at 1, 3, and 5 years was also similar for obese patients (71.5%, 36.3%, 24.3%) as for non-obese ones (60.2%, 43.7%, 27.7%; \( P = 0.969 \)).
Conclusion
Our propensity score-matched analysis strengthens the case that obesity does not adversely affect surgical outcomes of HCC patients undergoing curative hepatectomy.

Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world, and its incidence and mortality rate are increasing [1]. Surgical resection remains the most effective and practical treatment for HCC patients [2]. As surgical techniques as well as peri- and post-operative management of HCC patients have improved, morbidity and mortality rates have fallen significantly [3]. Nevertheless, long-term survival remains unsatisfactory owing to the high rates of recurrence and metastasis [4]. These poor clinical outcomes highlight the need for better understanding of the factors that affect prognosis. Such insights may improve decision-making about therapeutic modalities to treat HCC and reduce the risk of recurrence and metastasis.

Obesity is a serious global health problem: approximately 1.5 billion people around the world are overweight, and 671 million are obese [5]. Obesity, already linked to several disorders collectively known as "metabolic syndrome", including hypertension, cardiovascular disease and diabetes mellitus, is also now widely accepted as a significant risk factor for the development of various malignancies, including HCC [6,7].

Studies investigating whether obesity affects post-resection survival of HCC patients have given conflicting results. Some authors have reported lower overall survival (OS) or disease-free survival (DFS) rate in obese patients than in non-obese ones [8–10], while others have reported no significant differences between the two types of patients [11–17]. To help resolve the question of whether obesity influences postoperative outcomes in HCC patients, we retrospectively evaluated the influence of obesity on rates of postoperative complications, OS, and DFS in HCC patients.

Patients and Methods
The study protocol was approved by the institutional review board of the Tumor Hospital of Guangxi Medical University, Nanning, China. Written informed consent had been obtained from all patients prior to undergoing resection.

Patients
310 consecutive HCC patients with Child-Pugh A liver function who underwent curative hepatectomy as initial treatment at our hospital between December 2006 and December 2010 were eligible for inclusion in this study. BMI was calculated for each patient before surgery, and patients were classified into an obese group (BMI ≥25 kg/m²) or a non-obese group (BMI <25 kg/m²). World Health Organization (WHO) defines a BMI above 30 kg/m² for obesity. However, in China, the prevalence of individuals with such a BMI is no more than 3% [18], in contrast to 20%-30% prevalence in Western countries [19]. In China, the definition of obesity is proposed to be a BMI ≥25 kg/m² because of the incidence of obesity-related disorders increases with a BMI ≥25 kg/m² [20].
Curative hepatectomy

Indications for surgery were as follows: lack of ascites, hypersplenism, appropriate residual liver determined by volumetric computed tomography (CT), and presence of Child-Pugh A liver function [21]. Curative hepatectomy was defined to involve (1) complete removal of all nodules with the resection margin greater than 10 mm, (2) the absence of invasion of the main trunk and first-order branches of the portal vein, common hepatic duct and its first-order branches or main trunk of the hepatic vein and inferior vena cava (3) the absence of intra- or extra-hepatic metastasis, and (4) the absence of residual tumor or portal tumor thromboses on postoperative imaging. HCC diagnosis was confirmed by histopathological examination of surgical samples. Major resection was defined as the resection of three or more segments according to Couinaud’s classification [22,23]. The hepatectomy technique was performed as described [24].

Definitions of postoperative complications

Liver failure was defined based on increased international normalized ratio and hyperbilirubinemia on or after postoperative day 5 [25]. Bile leakage was defined as the occurrence of drainage fluid containing at least 3-fold higher bilirubin concentration than the serum bilirubin concentration on or after postoperative day 3, or as the need for radiological or surgical intervention due to biliary collection or bile peritonitis [26]. Wound infection was defined as the detection of bacteria in the wound exudate.

Follow-up

All patients were followed up at one month after surgery, then every 3 months for the rest of the first year, and every 6 months thereafter. Follow-up visits consisted of a physical examination, liver function tests, measurement of serum alpha-fetoprotein (AFP), abdominal ultrasonography and CT or magnetic resonance imaging (MRI). Postoperative antiviral therapy was rarely administered. OS was calculated as the time from the date of surgery until death from cancer, or complications due to underlying liver disease, or the date of the last follow up. DFS was calculated as the time from the date of surgery until detection of recurrent tumors or until the date of the last follow up without recurrence.

Treatment of recurrence

All patients showing recurrence or metastasis were evaluated for new treatment. Patients with intrahepatic recurrence were managed with repeat hepatectomy, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), or transarterial chemoembolization (TACE), depending on the severity of hepatic dysfunction and tumor number, size, and location. Patients with resectable metastatic tumors were treated by metastasectomy.

Propensity score matching

Propensity score analysis was used to reduce the bias in patient selection in observational studies. It seeks to eliminate confounding similarly to randomization, by creating comparison arms with similar distributions of measured baseline covariates [27]. Propensity scores were estimated using a logistic regression model based on age, gender, status of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, presence of diabetes mellitus, hypertension, cardiovascular diseases and respiratory diseases, platelet count, tumor number, tumor size, presence of liver cirrhosis, presence of tumor capsule, Barcelona Clinic Liver Cancer (BCLC) classification, AFP level, type of resection (minor or major), and liver function tests, including total bilirubin,
alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, and PT. Propensity score matching was performed using a 1:2 ratio without replacement and a caliper width of 0.1. The resulting subsets of score-matched obese and non-obese patients were used in subsequent analyses.

**Statistical analysis**

Clinicopathological variables, mortality, morbidity, and follow up data were summarized in S1 File. For continuous data, parametric analyses were performed using the t test; non-parametric analyses were performed using the Mann-Whitney U test. Categorical data were compared using the χ² test or Fisher’s exact test. OS and DFS were analyzed using the Kaplan-Meier method, and inter-group comparisons were performed using the log-rank test. Factors determined to be significant for OS and DFS using univariate analysis were introduced into a multivariate Cox proportional hazards model to determine adjusted hazard ratios (HRs) and associated 95% confidence intervals (CIs). All analyses were performed using SPSS 19.0 (IBM, USA). All statistical tests were two-sided, and P < 0.05 was considered statistically significant.

**Results**

**Characteristics of all study patients**

During the study period, 310 consecutive HCC patients with Child-Pugh A liver function undergoing curative hepatectomy were enrolled. Of these, 68 (22%) were obese based on BMI, and 242 (78%) were non-obese (Table 1). The obese group showed significantly evaluated levels of albumin and AST than did the non-obese group (P = 0.036, P = 0.043). However, the non-obese group showed a significantly higher frequency of multiple tumors (P = 0.006). The two groups were similar in age, gender, prevalence of diabetes mellitus, hypertension, cardiovascular diseases and respiratory diseases, HBV and HCV infection, serum bilirubin, AFP, ALT levels, platelet count, PT, tumor size, presence of tumor capsule, liver cirrhosis, BCLC stage and resection type (all P > 0.05). In addition, more than 89% of our cohort was infected with chronic HBV or HCV in both groups.

**Mortality and morbidity**

In the complete patient cohort, obese and non-obese groups showed similar 30-day mortality (1.5% vs. 2.5%, P = 1.000), 90-day mortality (4.4% vs. 5.0%, P = 0.706), and overall complication rate (25% vs. 17.4%, P = 0.156). Comparison of the distribution of postoperative complications between the two groups showed the only difference was the incidence of wound infection, which was significantly higher in the obese group than in the non-obese group (5.9% vs. 0.8%, P = 0.022; Table 2).

In the propensity score-matched groups, the two groups showed similar 30-day mortality (1.6% vs. 2.6%, P = 1.000), 90-day mortality (3.3% vs. 4.3%, P = 1.000) and similar overall complication rates (18% vs. 16.5%, P = 0.800). Obese patients tended toward higher incidence of postoperative wound infection (3.3% vs. 1.7%, P = 0.610).

**Overall survival analysis of all study patients**

Median follow-up time was 38.7 months (range, 1–80 months) in the obese group and 38.1 months (range: 1–81 months) in the non-obese group. During follow-up, 35 patients (51%) in the obese group and 132 (55%) in the non-obese group died of cancer or complications due to underlying liver disease (P = 0.653). Estimated OS rates at 1, 3, and 5 years were 85.3%, 65.9%,
and 46.2% in the obese group and 81.8%, 59.2%, and 44.4% in the non-obese group, respectively ($P = 0.717$, Fig 1A).

Dichotomized factors, including postoperative complications (present/absent), linked to survival were included in the survival analysis. Univariate analysis identified the following as prognostic factors predicting increased risk of mortality (Table 3): tumor size $>5$ cm ($P < 0.001$), BCLC B stage ($P = 0.048$) and major resection ($P < 0.001$). Of these factors, tumor size $>5$ cm was identified in multivariate Cox proportional hazard modeling as the only independent predictor of poor survival (HR 2.040, 95%CI 1.495 to 2.785, $P < 0.001$).

Disease-free survival analysis of all study patients

During follow-up, tumors recurred in 45 patients (66%) in the obese group and 173 (71%) in the non-obese group ($P = 0.397$). Estimated DFS rates at 1, 3, and 5 years were 71.5%, 39.3%, and 32.1% in the obese group and 61.7%, 40.8%, and 25.0% in the non-obese group, respectively ($P = 0.513$, Fig 1B).

Univariate analysis identified the following factors as associated with higher incidence of tumor recurrence after curative hepatectomy: AFP level $\geq 400$ ng/mL ($P = 0.015$), multiple

Table 1. Clinicopathological variables in non-obese patients (BMI $<25$ kg/m$^2$) and obese patients (BMI $\geq 25$ kg/m$^2$) with hepatocellular carcinoma from southeast China who underwent curative resection.

| Variable                          | Before Propensity Matching | After Propensity Matching |
|-----------------------------------|-----------------------------|---------------------------|
|                                   | Non-obese (n = 242)        | Obese (n = 68)            | P       | Non-obese (n = 115) | Obese (n = 61) | P       |
| BMI, kg/m$^2$                     | 21.2±2.0                   | 27.0±1.8                  | $<0.001$| 21.2±2.6           | 26.8±3.8       | $<0.001$|
| Age, yr                          | 49.2±11.9                  | 49.8±10.4                 | 0.723   | 49.6±11            | 50.3±10.6      | 0.728   |
| Male, n (%)                       | 210 (88.8)                 | 61 (89.7)                 | 0.520   | 102 (88.7)         | 54 (88.5)      | 0.973   |
| HBsAg positive, n (%)             | 209 (86.4)                 | 54 (79.4)                 | 0.158   | 96 (83.5)          | 50 (82.0)      | 0.800   |
| HCV antibody-positive, n (%)      | 10 (4.1)                   | 7 (10.3)                  | 0.095   | 7 (6.1)            | 4 (6.6)        | 1.000   |
| Comorbid disease, n (%)           |                            |                           |         |                    |                |         |
| Diabetes mellitus                 | 17 (7)                     | 4 (5.9)                   | 0.954   | 3 (2.6)            | 2 (3.3)        | 1.000   |
| Hypertension                      | 45 (18.6)                  | 18 (26.5)                 | 0.154   | 23 (20)            | 14 (23)        | 0.648   |
| Cardiovascular diseases           | 27 (11.2)                  | 6 (8.8)                   | 0.581   | 17 (14.8)          | 6 (9.8)        | 0.354   |
| Respiratory diseases              | 20 (8.3)                   | 7 (10.3)                  | 0.600   | 12 (10.4)          | 5 (8.2)        | 0.632   |
| Total bilirubin level, μmol/L     | 14±6.5                     | 13.9±6.5                  | 0.968   | 14.4±6.7           | 14.0±6.2       | 0.671   |
| AST, median (range), U/L          | 42.9 (24–53)               | 47.6 (30.3–55.8)          | $0.043$ | 42.1 (25–49)       | 44.7 (29–55)   | $0.136$ |
| ALT, median (range), U/L          | 48.8 (29–54)               | 44.4 (31–55.8)            | 0.954   | 43.7 (29–50)       | 44.7 (31–55.5) | 0.455   |
| Albumin, g/L                      | 40±4.6                     | 41.3±4.6                  | $0.036$ | 41.5±4.3           | 41±4.3         | 0.446   |
| Platelet count, 10$^9$/L          | 178.9±75.9                 | 177.6±73.1                | 0.900   | 174.2±63.4         | 176.0±73.9     | 0.865   |
| Prothrombin time, s               | 12.9±1.6                   | 12.9±1.9                  | 0.765   | 12.9±1.5           | 12.9±1.9       | 0.999   |
| AFP $\geq$400 ng/mL, n (%)        | 70 (28.9)                  | 17 (25.0)                 | 0.524   | 30 (26.1)          | 14 (23.0)      | 0.647   |
| Solitary tumor, n (%)             | 165 (68.2)                 | 58 (85.3)                 | $0.006$ | 93 (80.9)          | 5(18.3)        | 0.654   |
| Tumor size, median (range), cm    | 6 (3.5–8)                  | 5.3 (3.6–6.6)             | 0.154   | 5.6 (3.5–7.5)      | 5.2 (3.5–6.6)  | 0.647   |
| Tumor capsule, n (%)              | 135 (55.8)                 | 42 (61.8)                 | 0.379   | 49 (42.6)          | 23 (37.7)      | 0.529   |
| Liver cirrhosis, n (%)            | 188 (77.7)                 | 57 (83.8)                 | 0.272   | 95 (82.6)          | 5 (83.6)       | 0.867   |
| BCLC stage A/B, n (%)             | 194 (80.2)/48 (19.8)       | 60(88.2)/8(11.8)          | 0.126   | 97 (84.3)/18 (15.7)| 53 (86.9)/8 (13.1)| 0.652 |
| Minor/major resection, n (%)      | 105 (43.4)/137 (56.6)      | 31(45.6)/37(54.4)         | 0.747   | 56 (48.7)/59 (51.3)| 34(55.7)/27(44.3)| 0.374 |

Data are mean ± standard deviation or medium (25th-75th interquartile range) unless otherwise indicated

Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer.

doi:10.1371/journal.pone.0125649.t001

and 46.2% in the obese group and 81.8%, 59.2%, and 44.4% in the non-obese group, respectively ($P = 0.717$, Fig 1A).

Dichotomized factors, including postoperative complications (present/absent), linked to survival were included in the survival analysis. Univariate analysis identified the following as prognostic factors predicting increased risk of mortality (Table 3): tumor size $>5$ cm ($P < 0.001$), BCLC B stage ($P = 0.048$) and major resection ($P < 0.001$). Of these factors, tumor size $>5$ cm was identified in multivariate Cox proportional hazard modeling as the only independent predictor of poor survival (HR 2.040, 95%CI 1.495 to 2.785, $P < 0.001$).

Disease-free survival analysis of all study patients

During follow-up, tumors recurred in 45 patients (66%) in the obese group and 173 (71%) in the non-obese group ($P = 0.397$). Estimated DFS rates at 1, 3, and 5 years were 71.5%, 39.3%, and 32.1% in the obese group and 61.7%, 40.8%, and 25.0% in the non-obese group, respectively ($P = 0.513$, Fig 1B).

Univariate analysis identified the following factors as associated with higher incidence of tumor recurrence after curative hepatectomy: AFP level $\geq 400$ ng/mL ($P = 0.015$), multiple
tumors ($P = 0.002$), tumor size $> 5 \text{ cm}$ ($P < 0.001$), BCLC B stage ($P = 0.001$), and major resection ($P < 0.001$). Multivariate analysis identified the following significant predictors of tumor recurrence (Table 4): tumor size $> 5 \text{ cm}$ (HR 1.736, 95%CI 1.325 to 2.273, $P < 0.001$), and BCLC B stage (HR 1.650, 95%CI 1.188 to 2.290, $P = 0.003$).

**Propensity score matching of obese and non-obese patients**

Propensity score matching in the ratio 1:2 led to selection of 61 obese patients and 115 non-obese patients. The matched groups showed similar baseline characteristics (Table 1), indicating that the matching procedure worked well.

**Overall survival analysis of propensity score-matched patients**

Overall survival analysis of propensity-score matched patients showed that estimated OS at 1, 3, and 5 years was 83.6%, 63.6%, and 41.6% in the obese group, similar to the rates of 80.9%, 65.9%, and 49.1% in the non-obese group, respectively ($P = 0.358$, Fig 1C).

**Disease-free survival analysis of propensity score-matched patients**

Disease-free survival analysis of propensity-score matched patients showed that estimated DFS at 1, 3, and 5 years was 71.5%, 36.3%, and 24.3% in the obese group, similar to the 60.2%, 43.7%, and 27.7% in the non-obese group, respectively ($P = 0.969$, Fig 1D).

**Subgroup analysis of all study patients**

All HCC patients were categorized as non-obese (BMI < 25 kg/m$^2$), obese class I (BMI $\geq 25 \text{ kg/m}^2$), or obese class II (BMI $\geq 30 \text{ kg/m}^2$) groups. The non-obese, obese class I and obese class II groups comprised 242(78%), 61(20%) and 7(2%), respectively. The OS rates
of the obese class I (85.2%, 65.2% and 47.6% at 1, 3, 5 years, respectively) and obese class II (85.7%, 71.4% and 35.7% at 1, 3, 5 years, respectively) groups did not significantly differ from the non-obese group (81.8%, 59.2% and 44.4% at 1, 3, 5 years, respectively; P = 0.669 vs. obese class I group and P = 0.792 vs. obese class II group). The DFS rates of the obese class I

![Graph A](image1.png)  
**A** Cumulative survival

![Graph B](image2.png)  
**B** Disease-free survival

![Graph C](image3.png)  
**C** Cumulative survival

![Graph D](image4.png)  
**D** Disease-free survival

**Fig 1.** Survival of obese and non-obese patients with hepatocellular carcinoma after curative hepatectomy. Overall survival analyzed (A) before and (C) after propensity score matching. Disease-free survival (B) before and (D) after propensity score matching.

doi:10.1371/journal.pone.0125649.g001

Table 3. Univariate and multivariate analysis of factors predictive of poor overall survival in the entire cohort of obese and non-obese HCC patients after curative resection.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR                  | 95%CI                 | P      | HR                  | 95%CI                 | P      |
| Tumor size (>5 cm)         | 2.040               | 1.495–2.785           | <0.001 | 2.040               | 1.495–2.785           | <0.001 |
| BCLC stage (B)             | 1.458               | 1.004–2.119           | 0.046  |                     | 1.004–2.119           | 0.046  |
| Major resection            | 1.973               | 1.430–2.722           | <0.001 |                     | 1.430–2.722           | <0.001 |

**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; HR, hazard ratio; 95% CI, 95% confidence interval.

doi:10.1371/journal.pone.0125649.t003
Discussion

The present study suggests that obesity does not adversely affect OS, or risk of complications in HCC patients after curative resection. This is an important finding in light of the fact that obesity is directly associated with impairment of cardiac [28], pulmonary [29], and immunological functions [30], all of which can affect surgical outcomes.

The National Nutrition and Health Survey conducted in 2002 in China estimated that approximately 17.3% of Chinese are obese, based on the definition of BMI $\geq 25$ kg/m$^2$ [18]. In the present study, 68 of the 310 patients in our cohort (21.9%) were obese. This prevalence of obesity highlights the importance of understanding its effects on surgical risks and postoperative survival.

Studies of obesity and postoperative outcomes of various surgical procedures have given inconsistent results. Some authors have reported that elevated BMI is an independent predictor of morbidity [31,32], whereas others have argued that complications in obese patients are directly attributable to risk factors like smoking and diabetes, while high BMI by itself is not a risk factor for postoperative complications or death, with the possible exception of increased incidence of wound infection [33–36]. These differences may reflect the use of different definitions and classifications of obesity, different ways of reporting postoperative complications, differences in surgical procedure, and lack of statistical power. In the present study, the obese and non-obese groups showed similar mortality at 30 and 90 days and similar overall rates of postoperative complications following curative hepatectomy. Obese patients did show higher incidence of wound infection (5.9% vs. 0.8%, $P = 0.022$), consistent with the fact that obesity is a well-known risk factor for surgical site infection, especially wound infection, after hepatic resection [13,37]. However, this difference between our obese and non-obese cohorts became insignificant after adjusting for all confounding factors using propensity-score matching (3.3% vs. 1.7%, $P = 0.610$). It may be possible to counteract any added risk of infection in obese HCC patients using appropriate measures, such as a plastic adhesive drape impregnated with iodophor, a subcutaneous dressing impregnated with saline solution, and perioperative control of blood sugar level [8].

We measured similar OS for obese and non-obese patients, and obesity was not a risk factor for mortality in our cohort, as reported in other retrospective studies in Japan, Europe and

Table 4. Univariate and multivariate analysis of factors predictive of poor disease-free survival in the entire cohort of obese and non-obese HCC patients after curative resection.

| Variables             | Univariate analysis | Multivariate analysis |
|-----------------------|---------------------|-----------------------|
|                       | HR                  | 95%CI                 | $P$       | HR                  | 95%CI                 | $P$       |
| AFP($\geq400$ ng/mL)  | 1.439               | 1.075–1.1927          | 0.015     | 1.736               | 1.325–2.273           | $<$0.001  |
| Tumor number (multiple) | 1.583               | 1.188–2.109           | 0.002     |                     |                       |           |
| Tumor size (>5 cm)    | 1.784               | 1.363–2.334           | $<$0.001  | 1.650               | 1.188–2.290           | 0.003     |
| BCLC stage (B)        | 1.740               | 1.254–2.413           | 0.001     |                     |                       |           |
| Major resection       | 1.721               | 1.308–2.265           | $<$0.001  |                     |                       |           |

Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HR, hazard ratio; 95%CI, 95% confidence interval.

doi:10.1371/journal.pone.0125649.t004

(71.5%, 40.9% and 23.1% at 1, 3, 5 years, respectively) and obese class II (71.4%, 28.6% and 28.6% at 1, 3, 5 years, respectively) groups also did not significantly differ from the non-obese group (61.7%, 40.8% and 23.1% at 1, 3, 5 years, respectively; $P = 0.718$ vs. obese class I group and $P = 0.971$ vs. obese class II group).
America [11–17]. In fact, a few studies have suggested that elevated BMI is associated with improved OS [38,39]. This may reflect the fact that obese people have good nutritional and physiological reserves and show enhanced inflammatory response to injury, which may counteract comorbidity and mortality among obese patients undergoing hepatectomy [11,38]. On the other hand, some authors have reported that obesity worsens the prognosis of HCC patients [9,10]. Further studies are needed to clarify these differences before definitive conclusions can be made.

As with OS, we did not find significant differences in DFS between propensity score-matched obese and non-obese patients. This is consistent with several studies on obesity in HCC patients undergoing curative therapy [11,16,17]. HCC recurrence after curative hepatectomy occurs as a result of intrahepatic metastasis and multicentric carcinogenesis [40]. Theoretically, the former depends on factors related to HCC development such as tumor grade, vascular invasion, and microsatellite lesions; the latter, in contrast, is more likely related to underlying liver conditions such as cirrhosis and hepatitis. Obesity may enhance the risk of multicentric carcinogenesis by increasing oxidative stress, and it may hinder the detection of intrahepatic metastatic lesions, yet we found similar recurrence rates in obese and non-obese patients. It may be that obesity by itself does increase the risk of recurrence, but its effect is not as strong as those of other recurrence risk factors in Table 4. Further studies on primary HCC development are required to investigate the effects of obesity on hepatocarcinogenesis.

Our retrospective study is subject to several limitations. First, the sample size is relatively small, especially after propensity score matching. It would have been better to include a sufficiently large sample so that we could have analyzed patients in different BMI ranges, rather than somewhat arbitrarily adopting a single cut-off for obese or non-obese. Second, more than 89% of our cohort was infected with chronic HBV or HCV, unlike most HCC populations in other countries, the information of the severity of chronic hepatitis was unclear, and incidence of non-alcoholic steatohepatitis was also unclear in patients whose hepatitis was unrelated to either virus. Both these cohort characteristics may affect the accuracy of OS estimates. Third, BMI at diagnosis was used to classify patients as obese or non-obese, but weight may have changed substantially during follow-up; unfortunately, no data were collected on this. Lastly, follow-up was relatively short in this study. Our results should be confirmed in larger prospective studies with longer observation periods.

Conclusions

Obesity does not significantly increase incidence of complications or reduce OS or DFS in HCC patients from southwest China following curative hepatectomy.

Supporting Information

S1 File. Clinicopathological variables, mortality, morbidity, and follow up data of non-obese and obese patients with hepatocellular carcinoma after curative resection.

(ZIP)

Acknowledgments

The authors thank Armando Chapin Rodriguez, PhD for his language editing, which substantially improved the quality of the manuscript.
Author Contributions
Conceived and designed the experiments: LQL BDX. Performed the experiments: ZG JZ JHJ. Analyzed the data: ZG JHJ. Contributed reagents/materials/analysis tools: ZG. Wrote the paper: ZG.

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90. doi:10.3322/caac.20107 PMID: 21296855
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011; 53: 1020–1022. doi: 10.1002/hep.24199 PMID: 21374666
3. Llovet JM, Beaugrand M. Hepatocellular carcinoma: Present status and future prospects. J Hepatol. 2003; 38 Suppl 1: S136–S149. PMID: 12591191
4. Wu J, Huang Y, Chau G, Su C, Lai C, Lee P, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009; 51: 890–897. doi: 10.1016/j.jhep.2009.07.009 PMID: 19747749
5. Wise J. Obesity rates rise substantially worldwide. BMJ. 2014; 348: g3582. doi:10.1136/bmj.g3582 PMID: 24874848
6. Berentzen TL, Gamborg M, Holst C, Sorensen TI, Baker JL. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol. 2014; 60: 325–330. doi:10.1016/j.jhep.2013.09.015 PMID: 24076363
7. Bhaskaran K, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. The Lancet. 2014; 384: 755–765. doi: 10.1016/S0140-6736(14)60892-8 PMID: 25129328
8. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2013; 15: 504–510. doi: 10.1111/j.1477-2574.2012.00602.x PMID: 23750492
9. Saunders JK, Rosman AS, Neihaus D, Gouge TH, Melis M. Safety of hepatic resections in obese veterans. Arch Surg. 2012; 147: 331–337. doi: 10.1001/archsurg.2011.1404 PMID: 22184133
10. Siegel AB, Lim EA, Wang S, Brubaker W, Rodriguez RD, Goyal A, et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation. 2012; 94: 539–543. PMID: 22864187
11. Nishikawa H, Osaki Y, Takeda H, Sakamoto A, Saito S, Nishijima N, et al. Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013; 22: 173–181. PMID: 23799216
12. Utsunomiya T. Impact of obesity on the surgical outcome following repeat hepatic resection in Japanese patients with recurrent hepatocellular carcinoma. World J Gastroenterol. 2008; 14: 1553–1558. PMID: 18330947
13. Balzan S, Nagarajan G, Farges O, Galleano CZ, Dokmak S, Paugam C, et al. Safety of liver resections in obese and overweight patients. World J Surg. 2010; 34: 2960–2968. doi: 10.1007/s00268-010-0756-1 PMID: 20711580
14. Mathur AK, Ghaferi AA, Osborne NH, Pavlik TM, Campbell DA, Englesbe MJ, et al. Body mass index and adverse perioperative outcomes following hepatic resection. J Gastrointest Surg. 2010; 14: 1285–1291. doi: 10.1007/s11605-010-1232-9 PMID: 20532666
15. Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD. Safety of hepatic resection in overweight and obese patients with cirrhosis. Br J Surg, 2011; 98: 1147–1154. doi: 10.1002/bjs.7516 PMID: 21509752
16. Ohki T, Tateishi R, Shina S, Sato T, Masuzaki R, Yoshida H, et al. Obesity did not diminish the efficacy of percutaneous ablation for hepatocellular carcinoma. Liver Int. 2007; 27: 360–367. PMID: 17355458
17. Okamura Y, Maeda A, Matsunaga K, Kanemoto H, Uesaka K. Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012; 19: 449–457. doi: 10.1007/s00534-011-0461-9 PMID: 21983894
18. Potts M. Overweight and obesity in China. BMJ. 2006; 333: 361–362. PMID: 16916810
19. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA, 2001; 286: 1195–1200. PMID: 11595264
20. Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet. 2004; 363: 157–163. PMID: 14726171
21. Hsieh CB, Yu CY, Tzao C, Chu HC, Chen TW, Hsieh HF, et al. Prediction of the risk of hepatic failure in patients with portal vein invasion hepatoma after hepatic resection. Eur J Surg Oncol. 2006; 32: 72–76. PMID: 16246517

22. Dahiya D, Wu T, Lee C, Chan K, Lee W, Chen M. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: A 20-year experience. Surgery. 2010; 147: 676–685. doi: 10.1016/j.surg.2009.10.043 PMID: 20004441

23. Pol B, Campan P, Hardwigsen J, Botti G, Pons J, Le Treut YP. Morbidity of major hepatic resections: A 100-case prospective study. Eur J Surg. 1999; 165: 446–453. PMID: 10391161

24. Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage a hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: A propensity score-based analysis. Ann Surg Oncol. 2014; 21: 3069–3076. doi: 10.1245/s10434-014-3704-8 PMID: 24728740

25. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011; 149: 713–724. doi: 10.1016/j.surg.2010.10.001 PMID: 21236455

26. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatoabiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011; 149: 680–688. doi: 10.1016/j.surg.2010.12.002 PMID: 21316725

27. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014; 33: 1242–1258. doi: 10.1002/sim.5984 PMID: 24122911

28. Powell BD, Redfield MM, Bybee KA, Freeman WK, Rhal CS. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J Cardiol. 2006; 98: 116–120. PMID: 16749333

29. Santamaria F, Montella S, Pietrobelli A. Obesity and pulmonary disease: Unanswered questions. Obes Rev. 2012; 13: 822–833. doi:10.1111/j.1467-789X.2012.01008.x PMID: 22646804

30. Sartori S, Priante E, Pettenazzo A, Marson P, Suppiej A, Benini F, et al. Intrathecal synthesis of oligoclinal bands in rapid-onset obesity with hypothalamic dysfunction, hyperventilation, and autonomic dysregulation syndrome: New evidence supporting immunological pathogenesis. J Child Neurol. 2014; 29: 421–425. doi: 10.1177/0883073812469050 PMID: 23292759

31. Wagner BD, Grunwald GK, Rumsfeld JS, Hill JO, Ho PM, Wyatt HR, et al. Relationship of body mass index with outcomes after coronary artery bypass graft surgery. Ann Thorac Surg. 2007; 84: 10–16. PMID: 17583737

32. Pan W, Hindler K, Lee VV, Vaughn WK, Collard CD. Obesity in diabetic patients undergoing coronary artery bypass graft surgery is associated with increased postoperative morbidity. Anesthesiology. 2006; 104: 441–447. PMID: 16508390

33. Ardeshiri M, Faritous Z, Ojaghi Haghighi Z, Hosseini S, Baghaei R. Effect of obesity on mortality and morbidity after coronary artery bypass grafting surgery in iranian patients. Anesth Pain Med. 2014; 4: e18884. doi:10.5812/aapm.18884 PMID: 24977121

34. Blom RL, Lagarde SM, Klinkenbijl JHG, Busch ORC, Berge Henegouwen MI. A high body mass index in esophageal cancer patients does not influence postoperative outcome or long-term survival. Ann Surg Oncol. 2012; 19: 766–771. doi: 10.1245/s10434-011-1203-6 PMID: 21979112

35. Melis M, Weber JM, McLoughlin JM, Siegel EM, Hoffe S, Shridhar R, et al. An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol. 2011; 18: 824–831. doi: 10.1245/s10434-010-1336-1 PMID: 20865331

36. Wang H, Yang J, Zhang X, Yan L, Yang J. Liver resection in hepatitis B-related hepatocellular carcinoma: Clinical outcomes and safety in overweight and obese patients. PLOS ONE. 2014; 9: e99281. doi:10.1371/journal.pone.0099281 PMID: 24914932

37. Dindo D, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. Lancet. 2003; 361: 2032–2035. PMID: 12814714

38. Itosh I, Ikeda Y, Kawanaka H, Okuyama T, Kawasaki K, Eguchi D, et al. The effect of overweight status on the short-term and 20-y outcomes after hepatic resection in patients with hepatocellular carcinoma. J Surg Res. 2012; 178: 640–645. doi:10.1016/j.jss.2012.05.063 PMID: 22739047

39. Mathur AK, Ghaferi AA, Sell K, Sonnenday CJ, Englesbe MJ, Welling TH. Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. J Gastrointest Surg. 2010; 14: 849–857. doi: 10.1007/s11605-010-1163-5 PMID: 20140536

40. Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: Implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 2009; 16: 792–794. doi: 10.1245/s10434-009-0330-z PMID: 19190964